Actively Recruiting
Heat Shock Protein 47 in Thrombosis
Led by University of Aarhus · Updated on 2025-08-21
340
Participants Needed
2
Research Sites
142 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
A
Aarhus University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are: 1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event. Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
CONDITIONS
Official Title
Heat Shock Protein 47 in Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Informed consent
- For VTE group: Deep vein thrombosis confirmed by ultrasonography OR pulmonary embolism confirmed by computed tomography angiography (CTA)
- For AMI group: ST-segment elevation on electrocardiogram (ECG) AND culprit lesion(s) on coronary angiography
- For Stroke group: Stroke confirmed by magnetic resonance imaging AND atrial fibrillation detected on ECG, telemetry, or Holter monitoring AND stroke localized classically for atrial fibrillation (cortical, cerebellar, brainstem, or subcortical >1.5 cm in diameter)
- For Healthy group: Healthy individuals without known disease
You will not qualify if you...
- Under 18 years of age
- No informed consent
- Known hematological disorders
- Active hematological malignancy
- Severe renal insufficiency defined as eGFR less than 15 or on dialysis
- For VTE group: Pulmonary embolism incidentally detected by CTA done for reasons other than pulmonary embolism assessment without deep vein thrombosis
- For AMI group: Coronary dissection or Takotsubo cardiomyopathy
- For Stroke group: Stroke from other causes such as large vessel disease
- For Healthy group: Known acute or chronic disease or prior history of VTE, AMI, stroke, or other thromboembolic events
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Aarhus University Hospital
Aarhus, Central Region, Denmark, 8200
Actively Recruiting
2
Deutsches Herzzentrum de Charité
Berlin, State of Berlin, Germany, 12203
Actively Recruiting
Research Team
K
Kathrine A Friis, MD, PhD-fellow
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here